Affiliation:
1. Laboratory of Microbial Immunity, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
Abstract
Treatment with nontoxic monophosphoryl lipid A (MPL), which was derived from a polysaccharide-deficient, heptoseless Re mutant of Salmonella typhimurium, was found to inactivate suppressor T-cell activity, as evidenced by a decrease in the degree of low-dose immunological paralysis expressed and an increase in the magnitude of the antibody response to type III pneumococcal polysaccharide. The effects produced, which could not be attributed to the polyclonal activation of immune B cells by MPL, were dependent upon the dose of MPL used, as well as the time when MPL was given relative to low-dose priming or immunization with type III pneumococcal polysaccharide. Neither amplifier nor helper T-cell activity was decreased by treatment with the same, or larger, doses of MPL. The significance of these findings to the use of MPL as an immunological adjuvant or an immunomodulating agent is discussed.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference47 articles.
1. Regulation of the antibody response to type III pneumococcal polysaccharide;Baker P. J.;Rev. Infect. Dis.,1981
2. Direct evidence for the involvement of thymusderived (T) suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide;Baker P. J.;J. Immunol.,1982
3. Enhancement of the antibody response to type III pneumococcal polysaccharide in mice treated with anti-lymphocyte serum;Baker P. J.;J. Immunol.,1970
4. Increased amplifier T cell activity in autoimmune NZB mice and its possible significance in the expression of autoimmune disease;Baker P. J.;Immunobiology,1986
5. Cyclic development of immunological memory to bacterial lipopolysaccharide;Baker P. J.;Infect. Immun.,1985
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献